Although prostate cancer is a “cold tumor” in the traditional sense of immunotherapy, patients with cyclin-dependent kinase 12 (CDK12) and mismatch repair (MMR) gene alterations often benefit from immune checkpoint inhibitor (ICI) therapy [115]. This evidence concerns the gene CDK12 and prostate cancer.